Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A new comparison piece revisits three very different assets with the same starting bet: what $1,000 might have turned into over roughly 11 years.
THE APEX TIMES
THE APEX TIMES
Wall Street’s major indexes finished modestly higher Wednesday after a pickup in risk appetite tied to easing government bond yields. Shares of Moderna helped support the broader healthcare complex.
THE APEX TIMES
A market note tied Bank of America’s outlook to Medtronic’s still-strong near-term momentum, while pointing to another potential driver developing into a later date.
THE APEX TIMES
A widely discussed new Model Y variant, dubbed “Model Y L,” is being framed as a bid to reach customers Tesla is currently missing.
THE APEX TIMES
The next phase of the weight-loss and diabetes drug rivalry could hinge less on injections and more on whether either company can deliver effective oral GLP-1 therapies at scale.
THE APEX TIMES
Moderna shares rose sharply following a media report highlighting encouraging results from a melanoma vaccine study, with commentators calling the work a potential step toward a breakthrough in cancer therapy.
THE APEX TIMES
A sharp move higher in BioNTech shares followed a Moderna cancer vaccine development, but analysts at Leerink questioned whether the price momentum is likely to last.
THE APEX TIMES
Moderna said its personalized mRNA cancer vaccine Intismeran met its main goal in a melanoma study, a development investors are watching closely as the company resets expectations for its oncology pipeline.
THE APEX TIMES
AVGO declined in the afternoon session as a deal involving Marvell Technology to build custom artificial intelligence chips for Google renewed focus on the competitive stakes in the AI hardware market.
